Genetic risk tool could aid early diagnosis and treatment of multiple sclerosis patients

Young people could be spared from going blind by a new genetic risk tool that could also help diagnose multiple sclerosis (MS) earlier, to start effective treatments.

Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed – Biotech Investments

Kinarus Therapeutics Holding AG / Key word(s): Acquisition/Corporate Action 26-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The

April 27, 2024

Safety of Less-Radical Surgery for Early Cervical Cancer Gathers More Evidence

SAN DIEGO — The safety of non-radical approaches to surgery in early, low-risk cervical cancer gained additional support from a new prospective study, though fertility

March 19, 2024

Cetuximab biobetter by Shanghai Henlius Biotech for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.